[ad_1]
The World Health Organization (WHO) warns that decisions about the use of possible vaccines by governments against covid-19 should not take into account the nationality of the product. But its efficacy and safety.
“It’s not about nationality. It’s about science,” WHO spokeswoman Margaret Harris said Friday. His comment was made in response to a column question about President Jair Bolsonaro’s decision not to buy the Chinese product developed under an agreement with the Butantan Institute in São Paulo.
“We will not buy from China, it is my decision,” the president said Thursday. “I do not think that (the vaccine) provides enough security to the population due to its origin,” he said.
I believe that we will have the vaccine from other countries, including ours, which will transmit confidence to the population. That of China, unfortunately, there is already a lot of discredit on the part of the population, especially because, as many say, this virus would have been born there, “he added.
At WHO, evaluation is different. For the entity, what will determine the approval of a vaccine is its effectiveness and safety. And not who produces it. “We chose science,” Harris insisted.
According to her, no vaccine will be approved until the “highest standards” are reached.
The world may depend on Chinese supply
Internally, the international agencies that operate the Covax consortium warn that the reality is that the world may experience a heavy dependence on vaccines produced in China.
Based on production expansion estimates, the entities indicate that 49% of the world production of vaccines against covid-19 will come from China in 2023. That is, 7 billion doses. Brazil and the United States, together, would produce about 2 billion doses.
The Chinese team includes entities such as the Beijing Institute of Biological Products, SinoCellTech and Sinovac, the company that closed the deal with the São Paulo entity.
